Desarrollo de vacunas contra el COVID-19 en tiempo record

Development of vaccines against COVID-19 in record time

Palabras clave: SARS-COV-2, COVID-19, Vacunas

Resumen

La infección por SARS-CoV-2 es responsable del COVID-19 que ha afectado a millones de personas y muertes en el mundo, se necesita con urgencia vacunas a toda la población. En tal sentido, la tecnología moderna ha permitido el desarrollado de vacunas eficaces en distintas partes del mundo como Estados Unidos, Alemania, Reino Unido, Rusia, China entre otros; para controlar la pandemia por COVID-19. En esta revisión se detallaran las características de las vacunas que alcanzaron estudios de fase III y que actualmente se están aplicando en los esquemas de vacunación en la población mundial contra el COVID-19. Existen dudas si estas vacunas creadas en tiempo record producen inmunidad permanente o si protege contra mutaciones del SARS-CoV-2 y los efectos adversos a largo plazo.

Citas

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020;382(21):1969-1973.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, y cols; Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R, y cols; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-416.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley PK, y cols; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Dzharullaeva A, y cols; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671-681.

Bos R, Rutten L, van der Lubbe J, Bakkers M, Hardenberg G, Wegmann F, Zuijdgeest D, y cols. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020;5:91. doi: 10.1038/s41541-020-00243-x.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, y cols. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-2332.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, y cols. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181-192.

Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L, Li J, y cols. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396(10249):479-488.

Diken M, Kranz L, Kreiter S, Sahin U. mRNA: A versatile molecule for cancer vaccines. Curr. Issues Mol. Biol. 2017, 22,113-128.

Oliver S, Gargano J, Marin M, Wallace M, Curran K, Chamberland M, y cols. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924.

CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51.

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu S y cols. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020, 586, 567–571

CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129.

Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74.

Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020;8(11):e85-e86.

Oliver S, Gargano J, Scobie H, Wallace M, Hadler S, Leung J, cols. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(9):329-332.
Publicado
2021-04-30
Cómo citar
Mengual-Moreno, E., & Lizarzábal-García, M. (2021). Desarrollo de vacunas contra el COVID-19 en tiempo record: Development of vaccines against COVID-19 in record time. Revista Profesional HígadoSano, (20), 3-7. Recuperado a partir de https://produccioncientificaluz.org/index.php/higadosano/article/view/35785
Sección
Artículos